摘要
目的观察紫杉醇单药维持治疗中晚期非小细胞肺癌(NSCLC)的疗效及无进展生存期。方法 90例中晚期非小细胞肺癌患者给予一线含铂类的方案4周期化疗后,将达完全缓解(CR)、部分缓解(PR)及稳定(SD)患者53例分为2组。治疗组27例,给予紫杉醇维持治疗加最佳支持治疗3周期;对照组26例,仅给予最佳支持治疗,比较2组的有效率、无进展生存期及毒副反应。结果治疗组与对照组无进展生存期分别为(3.63±0.28)个月和(2.62±0.18)个月(P<0.05);疾病控制率(CR+PR+SD)分别为92.56%和57.69%(P<0.05);2组生活质量差异无统计学意义(P>0.05)。结论紫杉醇单药维持治疗中晚期非小细胞肺癌可提高疾病控制率、延长无进展生存期,生活质量不受影响,且毒副反应能耐受。
Objective To assess the efficacy and safety of Paclitaxel alone in the maintenance treatment of advanced non - small cell lung cancer. Methods Ninety patients who were diagnosed with advanced non - small cell lung cancer were enrolled in this study. After 4 cycles of standard eisplatin and other drugs ( Paclitaxel or gemcitabine and Navelbine) chemotherapy, 53 patients who did not progress were chosen and then they were randomly divided into treatment group ( n = 27) and control group ( n = 26). The patients in treatment group received paclitaxel alone and best supportive care, while the patients in control group received best supportive care. Pro- gression - free survival, total effective rates and drug adverse effects of two groups were compared and analyzed. Results Progression - free survival time ( PFS ) was 3.63 ± 0.28 months and 2.62 ± 0.18 months ( P = O. 004) for maintenance therapy group and control group respectively ;The total effective rates was 92.56% and 57.69% (P 〈 0.01 ) for maintenance therapy group and control group respective- ly. Quality of life between groups were not significant difference ( P 〉 0.05 ). Conclusions Paclitaxel alone in the maintenance treatment of advanced non - small cell lung cancer has satisfactory clinical efficacy, high PFS and high safety, and it is one of the best treatment options.
出处
《宁夏医学杂志》
CAS
2012年第11期1088-1090,共3页
Ningxia Medical Journal
基金
宁夏自然科学基金资助项目(NZ10186)
关键词
非小细胞肺癌
紫杉醇单药
维持治疗
无进展生存期
Non -small cell lung cancer
Paclitaxel alone
Maintenance treatment
Progression -free survival